AlphaStocks
6.2
Consider Buy

Alkermes plc. (ALKS)

As of Sep 20, 2026, Alkermes plc. (ALKS) scores 6.2/10 on AlphaStocks' five-model composite, #41 of 168 Health Care stocks. At $43, ALKS trades 12% above its model fair value of $39.

Health Care / Pharmaceuticals

S&P SmallCap 600

$43.42

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#41out of 168 in Health Care

Is Alkermes plc. a Good Investment in 2026?

Alkermes plc. (ALKS) scores 6.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates Alkermes plc. as Attractive (6/9). However, the Graham model rates it Caution — Significantly above fair value. Alkermes plc. currently trades 12% above its estimated fair value of $39. Alkermes plc. ranks #41 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E30.3ROE8.1Market Cap7B

Estimated Fair Value

$38.8112% above

Trading above estimated fair value. Eps growth of -34% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 1.4 · Fast Grower

Greenblatt

Neutral

Earnings yield 3.0% · ROC 16%

Frequently Asked Questions

Is Alkermes plc. (ALKS) a good investment?
As of Sep 20, 2026, Alkermes plc. (ALKS) scores 6.2/10 on AlphaStocks' five-model composite, #41 of 168 Health Care stocks. At $43, ALKS trades 12% above its model fair value of $39. That is a middle-of-the-pack score with no strong signal either way.
What is Alkermes plc.'s Piotroski F-Score?
Alkermes plc.'s Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ALKS overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $39, ALKS appears overvalued. The stock currently trades 12% above its estimated fair value. Trading above estimated fair value. Eps growth of -34% may not justify the premium.
How does ALKS compare to other Health Care stocks?
Alkermes plc. ranks #41 out of 168 stocks in the Health Care sector, placing it in the top 24% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about ALKS?
AlphaStocks evaluates ALKS using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 6.2/10.

Similar Stocks

AMPHLLYACAD

Compare ALKS with

ALKS vs AMPHALKS vs LLYACAD vs ALKS

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer